BioNTech
NEWS
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
COVID-19 would have claimed over 110,000 more lives in 2021 if vaccines weren’t available, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here’s a look at that story and more COVID-19 news.
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
Pfizer reported first-quarter revenues of $25.7 billion, a whopping 82% operational growth. This growth was largely driven by its COVID-19 vaccine developed with BioNTech and its antiviral drug, Paxlovid.
JOBS
IN THE PRESS